Literature DB >> 8041894

The molecular basis for cell cycle delays following ionizing radiation: a review.

A Maity1, W G McKenna, R J Muschel.   

Abstract

Exposure of a wide variety of cells to ionizing (X- or gamma-) irradiation results in a division delay which may have several components including a G1 block, a G2 arrest or an S phase delay. The G1 arrest is absent in many cell lines, and the S phase delay is typically seen following relatively high doses (> 5 Gy). In contrast, the G2 arrest is seen in virtually all eukaryotic cells and occurs following high and low doses, even under 1 Gy. The mechanism underlying the G2 arrest may involve suppression of cyclin B1 mRNA and/or protein in some cell lines and tyrosine phosphorylation of p34cdc2 in others. Similar mechanisms are likely to be operative in the G2 arrest induced by various chemotherapeutic agents including nitrogen mustard and etoposide. The upstream signal transduction pathways involved in the G2 arrest following ionizing radiation remain obscure in mammalian cells; however, in the budding yeast the rad9 gene and in the fission yeast the chk1/rad27 gene are involved. There is evidence indicating that shortening of the G2 arrest results in decreased survival which has led to the hypothesis that during this block, cells repair damaged DNA following exposure to genotoxic agents. In cell lines examined to date, wildtype p53 is required for the G1 arrest following ionizing radiation. The gadd45 gene may also have a role in this arrest. Elimination of the G1 arrest leads to no change in survival following radiation in some cell lines and increased radioresistance in others. It has been suggested that this induction of radioresistance in certain cell lines is due to loss of the ability to undergo apoptosis. Relatively little is known about the mechanism underlying the S phase delay. This delay is due to a depression in the rate of DNA synthesis and has both a slow and a fast component. In some cells the S phase delay can be abolished by staurosporine, suggesting involvement of a protein kinase. Understanding the molecular mechanisms behind these delays may lead to improvement in the efficacy of radiotherapy and/or chemotherapy if they can be exploited to decrease repair or increase apoptosis following exposure to those agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8041894     DOI: 10.1016/0167-8140(94)90408-1

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  58 in total

1.  Sensitivity of human glioma U-373MG cells to radiation and the protein kinase C inhibitor, calphostin C.

Authors:  M Acevedo-Duncan; J Pearlman; B Zachariah
Journal:  Cell Prolif       Date:  2001-02       Impact factor: 6.831

2.  Induction and characterization of human glioma clones with different radiosensitivities.

Authors:  J Wang; L Hu; N Gupta; T Shamseldin; T Ozawa; J Klem; M Cardell; D F Deen
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 3.  Cellular immunotherapy for soft tissue sarcomas.

Authors:  Steven Eric Finkelstein; Mayer Fishman; Anthony P Conley; Dmitry Gabrilovich; Scott Antonia; Alberto Chiappori
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

Review 4.  Control of the G2/M transition.

Authors:  George R Stark; William R Taylor
Journal:  Mol Biotechnol       Date:  2006-03       Impact factor: 2.695

5.  Integrin-dependent amplification of the G2 arrest induced by ionizing radiation.

Authors:  Celeste L Kremer; Monika Schmelz; Anne E Cress
Journal:  Prostate       Date:  2006-01-01       Impact factor: 4.104

6.  Loss of nuclear p21(Cip1/WAF1) during neoplastic progression to metastasis in gamma-irradiated p21 hemizygous mice.

Authors:  Robert W Engelman; Rosalind J Jackson; Domenico Coppola; Walker Wharton; Alan B Cantor; W Jack Pledger
Journal:  Exp Mol Pathol       Date:  2007-01-04       Impact factor: 3.362

7.  Susceptibility of peripheral lymphocytes of brain tumour patients to in vitro radiation-induced DNA damage, a preliminary study.

Authors:  Guruprasad Kalthur; Prem Kumar; Uma Devi; Sabir Ali; Ramya Upadhya; Sailaja Pillai; Anjali Rao
Journal:  Clin Exp Med       Date:  2008-09-13       Impact factor: 3.984

8.  Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses.

Authors:  Guozheng Guo; Yan Yan-Sanders; Beverly D Lyn-Cook; Tieli Wang; Daniel Tamae; Julie Ogi; Alexander Khaletskiy; Zhongkui Li; Christine Weydert; Jeffrey A Longmate; Ting-Ting Huang; Douglas R Spitz; Larry W Oberley; Jian Jian Li
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

9.  Mana-Hox displays anticancer activity against prostate cancer cells through tubulin depolymerization and DNA damage stress.

Authors:  Che-Jen Hsiao; Yunn-Fang Ho; John T-A Hsu; Wei-Ling Chang; Yi-Cheng Chen; Ya-Ching Shen; Ping-Chiang Lyu; Jih-Hwa Guh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-29       Impact factor: 3.000

10.  LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.

Authors:  Darlene Barnard; H Bruce Diaz; Teresa Burke; Gregory Donoho; Richard Beckmann; Bonita Jones; David Barda; Constance King; Mark Marshall
Journal:  Invest New Drugs       Date:  2015-11-27       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.